RESUMEN
"Difficult vascular anatomy" is a challenge for Interventional Radiologists especially in liver directed therapies such as trans arterial radio embolization. Trans arterial radio embolization is a long and difficult procedure in which the basic knowledge of hepatic and gastro-enteric vascularization, with its high degree of variations, is very important in order to correctly administer the therapeutic drug selectively. In this report, we present a case of an atypical patient affected by an unresectable hepatocellular carcinoma, candidate for Radio-embolization treatment. His vascular anatomy was very difficult to manage, but the Interventional Radiologist was not only able to go over the "difficult anatomy," but also to take advantage of it.
RESUMEN
Rheumatoid arthritis (RA) is an incapacitating chronic inflammatory disease of the joints that, because of frequent relapses, requires life-long treatment. In patients affected with RA an important treatment objective is to achieve specific immune suppression in order to extinguish the immune process and arrest the disease, thus preventing or delaying complications and avoiding disease recurrence. The side effects of anti-inflammatory drugs given to improve the quality of life of these patients can be reduced with the use of specific immune therapies that block, as selectively as possible, the pathologic mechanism responsible for the disease. New therapeutic options for specific, targeted therapies for treating RA are being developed, and trials to assess the efficacy and safety of these approaches are underway. However, these therapies rely primarily on clinical assessment to evaluate treatment efficacy. It would be useful, therefore, to have an objective and reliable method that directly highlights the immune processes underlying the disease. Currently available radiopharmaceuticals for imaging RA, with a special emphasis on recently developed agents and their use in therapy decision-making and follow-up are the focus of this article.
Asunto(s)
Artritis Reumatoide/diagnóstico por imagen , Aumento de la Imagen/métodos , Tomografía de Emisión de Positrones/tendencias , Radioisótopos , Radiofármacos , HumanosRESUMEN
Over the past 20 years, radiopharmaceutical research has brought to market a wide variety of drugs that aid in the management of infection and inflammation. Finding the best clinical application for existing radiopharmaceuticals can be a challenging task, as clinicians now have to choose from an array of many different radiopharmaceuticals, each suited to identify a specific type of inflammation. With this review, we describe the features of receptor-targeting agents and present the main advantages and limitations to their application in the diagnosis of inflammation and infection. The receptor-specific agents described here include peptides and antibodies as well as radiolabeled antibodies employed for the specific targeting of neutrophils, bacteria, lymphocytes, and molecules involved in inflammatory processes. Because these agents bind to specific receptors, they allow the mapping of receptor expression in vivo. Such mapping represents the future of nuclear medicine imaging, as it aids in diagnosing the type of inflammation, in therapy decision-making, in selecting suitable candidates for therapy, and in evaluating treatment efficacy.
Asunto(s)
Enfermedades Transmisibles/diagnóstico por imagen , Enfermedades Transmisibles/metabolismo , Sistemas de Liberación de Medicamentos/métodos , Inflamación/diagnóstico por imagen , Inflamación/metabolismo , Receptores de Superficie Celular/metabolismo , Humanos , Técnicas de Sonda Molecular , Tomografía de Emisión de Positrones/métodos , Tomografía de Emisión de Positrones/tendencias , Radiofármacos/farmacocinéticaRESUMEN
BACKGROUND: It has been recently demonstrated that apoptosis is involved in beta-cell destruction in the NOD mouse model of diabetes. The aim of the present study was to investigate whether IL-15, a cytokine involved in the modulation of the apoptotic process, is capable of modifying the natural history of diabetes and/or insulitis in pre-diabetic NOD mice. The rationale for the use of IL-15-IgG2b recombinant cytokine is related to its long half-life (28 +/- 4 h). METHODS: At 10 weeks of age, 2 groups of 24 female mice were treated with single or multiple i.p. doses of IL-15-IgG2b respectively. As control, 2 groups of 24 age- and litter-matched female mice were injected intra-peritoneally with single or multiple doses of IgG2b immunoglobulin. RESULTS: Diabetes incidence at 33 weeks of age was lower in the group of mice treated with multiple doses than in the control group (p = 0.03). The cumulative incidence of diabetes at 33 weeks of age between single-dose treated mice and the control group was similar. No significant differences in the calculated index of insulitis were observed in all treated and control mice. CONCLUSIONS: We conclude that IL-15-IgG2b reduces the cumulative incidence of diabetes, without affecting the extent and severity of the insulitis process. Considering this and the well-defined anti-apoptotic effects of IL-15, we suggest that the reduction of diabetes incidence could be due to a down-regulation of beta-cell apoptosis.
Asunto(s)
Diabetes Mellitus Tipo 1/prevención & control , Interleucina-15/farmacología , Proteínas Recombinantes de Fusión/farmacología , Animales , Diabetes Mellitus Tipo 1/epidemiología , Glucosuria , Humanos , Inmunoglobulina G/farmacología , Incidencia , Ratones , Ratones Endogámicos NOD , Factores de TiempoRESUMEN
We describe in detail the labelling of interleukin-2 with I ( I-IL2), its biochemical characterization, the binding assay and its use for the detection of tissues infiltrated with mononuclear cells. Human recombinant IL2 was labelled using an enzymatic method and its biochemical characterization was performed using high performance liquid chromatography (HPLC) analysis of cyanogen bromide-cleaved protein. biological and binding assays were performed on CTLL-2 cell line and on activated peripheral blood lymphocytes. studies were performed 1 h after administration of 2-3 mCi of I-IL2 in 10 newly diagnosed type 1 diabetes patients, five pre-diabetic patients, 10 Hashimoto's thyroiditis patients, 10 coeliac disease patients and 10 normal volunteers. I-IL2 scintigraphy allowed the detection and quantification of activated mononuclear cells in several affected tissues. In detail, I-IL2 accumulation was detected in the thyroid of all patients affected by Hashimoto's thyroiditis, in the bowel of all coeliac disease patients and in the pancreas of all pre-type 1 diabetic patients. By contrast, in newly diagnosed type 1 diabetics, I-IL2 scan was positive in five of the 10 studied patients. I-IL2 scintigraphy may be useful for studying autoimmune phenomena and in diagnostic protocols to evaluate the presence of other tissue involvement in patients with an organ-specific autoimmune disease.
Asunto(s)
Enfermedades Autoinmunes/diagnóstico por imagen , Diabetes Mellitus/diagnóstico por imagen , Interleucina-2/farmacocinética , Radioisótopos de Yodo , Linfocitos/diagnóstico por imagen , Adolescente , Adulto , Secuencia de Aminoácidos , Enfermedad Celíaca/diagnóstico por imagen , Enfermedad Celíaca/inmunología , Células Cultivadas , Niño , Diabetes Mellitus/inmunología , Diabetes Mellitus Tipo 1/diagnóstico por imagen , Femenino , Humanos , Interleucina-2/química , Marcaje Isotópico/métodos , Recuento de Linfocitos , Masculino , Datos de Secuencia Molecular , Valores de Referencia , Reproducibilidad de los Resultados , Tiroiditis Autoinmune/diagnóstico por imagen , Tomografía Computarizada de Emisión de Fotón Único , Tomografía Computarizada por Rayos XRESUMEN
Radiolabelled peptides are an emerging class of radiopharmaceuticals that share chemical and biological properties. From the chemical point of view they have a poly-amino acid structure varying from 3 to more that 200 amino acids, and they are labelled with different isotopes directly or by a linker. Biologically, they bind to specific cell membrane receptors, thus providing in vivo histopathological information for diagnostic purposes, therapy follow-up or targeted radiotherapy. This paper reviews most of the radiolabelled peptides that have been tested in animals and humans in the fields of oncology, neurology, cardiology, inflammation/infection, atherosclerosis and thrombosis. A new classification is also proposed for peptides targeting tumour cells based on the biological function of target receptors. These tailored radiopharmaceuticals are the basis of the new era of "molecular nuclear medicine".
Asunto(s)
Péptidos/uso terapéutico , Radiofármacos/uso terapéutico , Arteriosclerosis/diagnóstico por imagen , Arteriosclerosis/radioterapia , Humanos , Infecciones/diagnóstico por imagen , Infecciones/radioterapia , Inflamación/diagnóstico por imagen , Inflamación/radioterapia , Neoplasias/diagnóstico por imagen , Neoplasias/radioterapia , Enfermedades del Sistema Nervioso/diagnóstico por imagen , Enfermedades del Sistema Nervioso/radioterapia , Cintigrafía , Trombosis/diagnóstico por imagen , Trombosis/radioterapiaRESUMEN
The diagnosis of inflammatory processes is an important goal in medicine. In some cases the diagnosis is easy, based on the clinical history and the physical examination of the patient. Other cases are more difficult to diagnose because they are asymptomatic or with non-specific symptoms. Thus, several imaging techniques have been developed for the diagnosis of inflammatory processes, from the simple X-ray to the more sophisticated computerised tomography, magnetic resonance imaging and nuclear medicine scan. They provide different information and their role in different diseases will be discussed in this review with particular emphasis on the expanding field of the use of radiolabelled cytokines for imaging infection/inflammation. So far, IL-1, IL-1ra, IL-2, IL-6, IL-8, IL-10, IL-12 p40, G-CSF, IFN-gamma and EGF have been radiolabelled for in vivo targetting of different leukocyte subsets with promising results for their clinical use.
Asunto(s)
Citocinas , Infecciones/diagnóstico , Inflamación/diagnóstico , Radiofármacos , Animales , Humanos , Ligandos , Imagen por Resonancia Magnética , Espectroscopía de Resonancia Magnética , Ratones , Cuello/diagnóstico por imagen , Cintigrafía , Tiroiditis/diagnóstico por imagen , Tomografía Computarizada por Rayos X , Rayos XRESUMEN
Coeliac disease is diagnosed by the presence of specific antibodies and a jejunal biopsy showing mucosal atrophy and mononuclear cell infiltration. Mucosal cell-mediated immune response is considered the central event in the pathogenesis of coeliac disease, and untreated coeliac patients show specific features of T-cell activation in the small intestine. Here we describe the use of iodine-123-interleukin-2 scintigraphy in coeliac patients as a non-invasive tool for detection of lymphocytic infiltration in the small bowel and its use for therapy follow-up, and we demonstrate the specificity of binding of labelled-IL2 to activated lymphocytes by ex-vivo autoradiography of jejunal biopsies. 123I-IL2 was administered i.v. [74 MBq (2 mCi)], and gamma camera images were acquired after 1 h. Ten patients were studied with 123I-IL2 scintigraphy at diagnosis and seven were also investigated after 12-19 months of gluten-free diet. Results were expressed as target-to-background radioactivity ratios in six different bowel regions before and after the diet. At the time of diagnosis all patients showed a significantly higher bowel uptake of 123I-IL2 than normal subjects (P < 0.003 in all regions). A significant correlation was found between jejunal radioactivity and the number of IL2R + ve lymphocytes per millimetre of jejunal mucosa as detected by immunostaining of jejunal biopsy (r2 = 0.66; P = 0.008). Autoradiography of jejunal biopsies confirmed that labelled-IL2 only binds to activated T-lymphocytes infiltrating the gut mucosa. After 1 year of the diet, bowel uptake of 123I-IL2 significantly decreased in five out of six regions (P < 0.03), although two patients still had a positive IL2 scintigraphy in one region. We conclude that 123I-IL2 scintigraphy is a sensitive non-invasive technique for assessing in vivo the presence of activated mononuclear cells in the bowel of patients affected by coeliac disease. Unlike jejunal biopsy, this method provides information from the whole intestine and gives a non-invasive measure of the effectiveness of the gluten-free diet.
Asunto(s)
Enfermedad Celíaca/diagnóstico por imagen , Enfermedad Celíaca/dietoterapia , Interleucina-2 , Radioisótopos de Yodo , Yeyuno/patología , Linfocitos/patología , Adulto , Biopsia , Enfermedad Celíaca/patología , Femenino , Estudios de Seguimiento , Humanos , Yeyuno/diagnóstico por imagen , Masculino , Cintigrafía , Factores de TiempoRESUMEN
UNLABELLED: Activated mononuclear cells expressing interleukin-2 (IL2) receptors (IL2-Rs) heavily infiltrate the Crohn's disease (CD) gut wall. A new technique for the in vivo detection of tissue infiltrating IL2-R positive (IL2R+ve) cells was developed based on 123I-IL2 scintigraphy. The aim of this study was to investigate whether 123I-IL2 accumulates in the CD gut wall in different phases of the disease and to evaluate the specificity of 123I-IL2 binding to activated IL2R+ve cells infiltrating the gut wall. METHODS: Fifteen patients with ileal CD (10 active and 5 inactive) and 10 healthy volunteers were studied by 123I-IL2 scintigraphy. Six patients with active CD were studied before and after 12 wk of steroid treatment. After scintigraphy, patients were followed up for 29-54 mo. Ex vivo autoradiography was performed to determine specificity of 125I-IL2 binding to IL2R+ve cells. For bowel scintigraphy, 123I-IL2 (75 MBq) was injected intravenously and gamma camera images were acquired after 1 h. Bowel radioactivity was quantified in 64 regions of interest (ROIs). RESULTS: Autoradiography showed specific binding of 125I-IL2 to IL2R+ve mononuclear cells infiltrating the CD gut wall. Intestinal 123I-IL2 uptake assessed by the number of positive ROIs was higher in patients with active or inactive CD than in healthy volunteers (P < 0.0001 and P = 0.03, respectively) and positively correlated with the CD activity index (P = 0.01). 123I-IL2 intestinal uptake significantly decreased in patients with CD in steroid-induced remission (P = 0.03). A significant correlation was observed between the number of positive ROIs and time to disease relapse. CONCLUSION: 123I-IL2 accumulates in the diseased CD gut wall by specific binding to IL2R+ve cells, infiltrating the involved tissues. 123I-IL2 scintigraphy may be an objective tool for the in vivo assessment of intestinal activated mononuclear cell infiltration.
Asunto(s)
Enfermedad de Crohn/diagnóstico por imagen , Interleucina-2 , Radioisótopos de Yodo , Adulto , Autorradiografía , Estudios de Casos y Controles , Femenino , Humanos , Íleon/diagnóstico por imagen , Interleucina-2/farmacocinética , Masculino , Cintigrafía , Receptores de Interleucina-2/metabolismo , Sensibilidad y EspecificidadRESUMEN
The relationship between Fas-mediated apoptosis and Type 1 diabetes is currently under investigation. Fas/Fas ligand interaction could be involved both in the insulitis process and in beta-cell death. Nevertheless, different mechanisms appear to be involved in human Type 1 diabetes and in NOD mice. In the present work, we review recent evidence of the role of the Fas/Fas ligand system in human and NOD mouse diabetes, describing possible hypotheses for its involvement in the pathogenesis of the disease, with possible implications for therapy and islet transplantation.
Asunto(s)
Apoptosis/fisiología , Enfermedades Autoinmunes , Diabetes Mellitus Tipo 1/inmunología , Receptor fas/fisiología , Animales , Diabetes Mellitus Tipo 1/cirugía , Humanos , Trasplante de Islotes Pancreáticos , Ratones , Ratones Endogámicos NODRESUMEN
Insulin-dependent type 1 diabetes (IDDM) is caused by the autoimmune destruction of insulin-producing beta cells. Approximately 10%-20% of patients may benefit from adjuvant immunotherapy upon diagnosis of the disease in order to protect residual beta-cell function. It has been suggested that this subgroup of patients differs from others by virtue of the presence of residual pancreatic inflammation and beta-cell function. In this study we have investigated to what extent technetium-99m-labelled human polyclonal immunoglobulins (99mTc-HIG) accumulate in the pancreas of IDDM patients at the time of diagnosis and 1 year thereafter, with a view to ascertaining whether HIG scintigraphy is useful for the identification of IDDM patients with residual pancreatic inflammation. Patients with recent-onset IDDM (n=15) were investigated at the time of diagnosis and 1 year later, and ten age- and sex-matched normal subjects were also studied. Gamma camera imaging and target to background ratio, analysed blind by three independent readers, were used to quantify the radioactivity in the pancreatic region and findings were correlated with metabolic, immunological and clinical parameters. Seven out of 15 newly diagnosed IDDM patients showed a significant accumulation of radiolabelled HIG in the pancreas (pancreas/bone ratio higher than the mean +2SD of normal subjects). One year after diagnosis, pancreatic accumulation of HIG was still detectable in most IDDM patients who were positive at the time of diagnosis. Six out of seven patients with positive scintigraphy had a partial clinical remission. These results indicate that HIG scintigraphy at the time of onset of diabetes identifies a subset of patients with residual beta-cell function who may benefit from adjuvant immunotherapy.
Asunto(s)
Diabetes Mellitus Tipo 1/diagnóstico por imagen , Inmunoglobulinas , Islotes Pancreáticos/diagnóstico por imagen , Tecnecio , Adolescente , Diabetes Mellitus Tipo 1/epidemiología , Diabetes Mellitus Tipo 1/fisiopatología , Femenino , Estudios de Seguimiento , Humanos , Islotes Pancreáticos/fisiopatología , Masculino , Pronóstico , Cintigrafía , Factores de TiempoRESUMEN
In insulin-dependent (type 1) diabetes mellitus, increasing peripheral insulin sensitivity might be a useful approach in controlling the process leading to beta cell destruction by reducing insulin output and thereby reducing the antigenicity associated with its release. The aim of this study was to investigate whether the use of a biguanide, Metformin, which has been suggested to increase insulin sensitivity, was capable of modifying the natural history of diabetes in a model of type 1 diabetes, the non-obese diabetic (NOD) mouse. Using age-, sex- and litter-matched groups, three groups of 32 animals each were treated with Metformin in their drinking water at a high dose of 200 mg/kg body weight and at a low dose of 20 mg/kg body weight; the third group of mice acted as controls. Diabetes incidence at 30 weeks of age was similar in all groups. No significant differences in the calculated index of insulitis were observed in treated or control animals. We conclude that Metformin does not affect the disease process leading to clinical diabetes in this animal model.
Asunto(s)
Diabetes Mellitus Tipo 1/prevención & control , Hipoglucemiantes/farmacología , Metformina/farmacología , Envejecimiento/fisiología , Animales , Glucemia/metabolismo , Diabetes Mellitus Tipo 1/patología , Femenino , Glucosuria/metabolismo , Islotes Pancreáticos/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos NODRESUMEN
The non-obese diabetic (NOD) mouse is widely used to study the pathogenesis of insulin-dependent diabetes mellitus. However, the mechanisms responsible for beta-cell destruction, in this model, are still poorly defined. The CD95/CD95L system among other effector systems has been implicated in beta-cell death. In this study we investigated in NOD, non-obese resistant (NOR) and Balb/c mice the expression of CD95 and CD95L in alpha and beta pancreatic cells by immunohistochemistry and immunofluorescence. We demonstrate that alpha cells in the islets of Langherans constitutively express CD95L forming a natural shield around beta cells.
Asunto(s)
Islotes Pancreáticos/química , Glicoproteínas de Membrana/análisis , Receptor fas/análisis , Animales , Diabetes Mellitus Tipo 1/inmunología , Diabetes Mellitus Tipo 1/patología , Proteína Ligando Fas , Femenino , Técnica del Anticuerpo Fluorescente , Técnicas para Inmunoenzimas , Islotes Pancreáticos/inmunología , Islotes Pancreáticos/patología , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos NOD , Ratones EndogámicosRESUMEN
OBJECTIVE: The possibility to quantify in vivo the severity of the inflammatory process in the pancreas of patients with recent onset insulin dependent diabetes mellitus (IDDM) could be of great relevance for follow-up studies involving immunotherapy. Scintigraphy with radiolabelled human polyclonal immunoglobulins (99mTc-HIG) is currently used for the diagnosis and follow-up of several acute and chronic inflammatory diseases. In this longitudinal study we have investigated to what extent 99mTc-HIG accumulate in the pancreas of patients with recent onset IDDM and in subjects at risk to develop IDDM. METHODS: Combined computerised tomography and gamma camera imaging were used to measure the radioactivity in the pancreatic region, as the pancreas/bone radioactivity ratio (P/B). Patients with IDDM (n = 15) were investigated at the time of diagnosis and after 1 year. Five pre-diabetic ICA+ve subjects and 8 age and sex matched normal subjects were also investigated. RESULTS: Eight out of 15 newly diagnosed IDDM patients and 2/5 ICA+ve subjects showed a significant accumulation of radiolabelled HIG in the pancreas (P/B higher than the upper 1st centile of normal subjects). One year after the diagnosis a significant accumulation of immunoglobulins was still detectable in the pancreas of IDDM patients positive who were positive at diagnosis. CONCLUSIONS: These results suggest that immunoglobulins home and bind to the pancreas of patients with recent onset IDDM and also in some ICA+ve individuals. This may reflect an increased vascular permeability of pancreatic capillaries as a consequence of the inflammatory process involving the islets. Thus, this technique may be useful for monitoring the efficacy of immune intervention at diagnosis.
Asunto(s)
Diabetes Mellitus Tipo 1/diagnóstico por imagen , Inmunoglobulinas Intravenosas , Páncreas/diagnóstico por imagen , Adolescente , Adulto , Anatomía Transversal/métodos , Glucemia/análisis , Niño , Diabetes Mellitus Tipo 1/patología , Femenino , Estudios de Seguimiento , Humanos , Islotes Pancreáticos/inmunología , Masculino , Páncreas/patología , Radioisótopos , Cintigrafía , TecnecioAsunto(s)
Enfermedades Autoinmunes/diagnóstico por imagen , Autoinmunidad/fisiología , Enfermedad Celíaca/diagnóstico por imagen , Interleucina-2 , Receptores de Interleucina-2/metabolismo , Abdomen/diagnóstico por imagen , Adolescente , Adulto , Enfermedades Autoinmunes/metabolismo , Enfermedad Celíaca/metabolismo , Niño , Enfermedad de Crohn/diagnóstico por imagen , Femenino , Enfermedad de Graves/diagnóstico por imagen , Humanos , Inyecciones Intravenosas , Interleucina-2/administración & dosificación , Interleucina-2/análisis , Interleucina-2/metabolismo , Radioisótopos de Yodo , Masculino , Persona de Mediana Edad , Cuello/diagnóstico por imagen , Cintigrafía , Proteínas Recombinantes/análisis , Proteínas Recombinantes/metabolismo , Tiroiditis Autoinmune/diagnóstico por imagenRESUMEN
We have investigated the presence of somatostatin receptors on the cell surface of metastatic medullary thyroid carcinoma in vivo using 111In-Octreotide scintigraphy. Five patients were studied before and three months after therapy with octreotide (300-600 micrograms/day). After each 111In-Octreotide scintigraphy the target/background (T/B) radioactivity ratio was calculated for each detectable metastases. A total of 14/18 metastases showed a reduction in the T/B ratio after therapy, suggesting saturation or down-regulation of the somatostatin receptors on metastases induced by octreotide therapy. Patients also showed a reduction in serum calcitonin levels after therapy. We conclude that 111In-Octreotide scintigraphy may be useful in medullary thyroid carcinoma to evaluate the rationale for somatostatin therapy and to monitor the effect of treatment.
Asunto(s)
Antineoplásicos Hormonales/uso terapéutico , Carcinoma Medular/secundario , Regulación hacia Abajo , Radioisótopos de Indio , Octreótido/análogos & derivados , Octreótido/uso terapéutico , Radiofármacos , Receptores de Somatostatina/efectos de los fármacos , Neoplasias de la Tiroides/diagnóstico por imagen , Adulto , Anciano , Calcitonina/sangre , Carcinoma Medular/diagnóstico por imagen , Carcinoma Medular/tratamiento farmacológico , Femenino , Estudios de Seguimiento , Humanos , Neoplasias Pulmonares/diagnóstico por imagen , Neoplasias Pulmonares/secundario , Metástasis Linfática/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Compuestos de Organotecnecio , Receptores de Somatostatina/análisis , Succímero , Ácido Dimercaptosuccínico de Tecnecio Tc 99m , Neoplasias de la Tiroides/tratamiento farmacológico , Tomografía Computarizada de Emisión de Fotón Único , Tomografía Computarizada por Rayos XRESUMEN
We evaluated the sensitivity of 111In-Octreotide scintigraphy in the diagnosis of pancreatic insulinoma in a selected number of patients. In addition, we compared the results of scintigraphy with those of other conventional diagnostic techniques. Seven patients with surgically confirmed insulinoma (< 1.5 cm in diameter) of the pancreas were studied. Before surgery, patients underwent arteriography with Ca-gluconate, CT scan, and 111In-Octreotide scintigraphy. 111In-Octreotide scintigraphy showed a higher diagnostic specificity (85%) than selective arteriography (83%) or CT scan (57%). We conclude that 111In-Octreotide scintigraphy should always be performed before surgery in cases of pancreatic insulinoma and that a SPECT acquisition should be performed both 6 and 24 hours post-injection in order to increase the diagnostic sensitivity of the test.